European Companies Search Engine
European Union Transparency Register Eutr7 Mar 2026 European Union Transparency Register
Overview
Text
BioNTech SE
Identification Code: 516273537966-42 Registration Date: 2020-05-04 Last Update Date: 2026-03-05 Entity Form: Societas Europaea Website: https://biontech.de/ Registration Category: Companies & groups
Contact Information
Head Office: An der Goldgrube 12 55131 Mainz GERMANY Phone: +49 6131 90840
EU Office: An der Goldgrube 12 55131 Mainz GERMANY Phone: +49 6131 90840
Goals
Biopharmaceutical New Technologies (BioNTech) is a global next-generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
Levels of Interest
- Global
EU Legislative Proposals and Initiatives
- Interactions with the European Commission regarding activities relating to mRNA drugs and vaccines, including its COVID-19 vaccine.
- Commission proposal for the Pharmaceutical Directive
- Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies (‘MAV+’)
- African Vaccines Manufacturing Accelerator (AVMA)
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- Critical Medicines Act
- EU Biotech Act
- Health Technology Assessment (HTA)
EU Supported Forums and Platforms
N/A
Inter- or Unofficial Groupings
N/A
Members
- Number of members: 5
- Members (10%): 5
- FTE: 0.5
- Additional Information: N/A
European Parliament Accredited Persons
0
Interests
- Public health
- Research and innovation
Structure
Is Member Of: See above.
Organisation Members:
- AusBiotech Ltd
- Biotechnologie-Industrie-Organisation Deutschland e.V. (BIO Deutschland e.V.)
- Bundesdeutscher Arbeitskreis für Umweltbewusstes Management (B.A.U.M.) e.V.
- Chambre de Commerce et D’Industrie France-Amerique
- DECHEMA Gesellschaft für Chemische Technik und Biotechnologie e.V.
- econsense – Forum Nachhaltige Entwicklung der Deutschen Wirtschaft e.V.
- European Confederation for Pharmaceutical Entrepreneurs (EUCOPE)
- European Society for Medical Oncology
- Freiwillige Selbstkontrolle für die Arzneimittelindustrie e.V.
- gesundheitswirtschaft rhein-main e.V.
- Hessenchemie – Arbeitgeberverband Chemie und verwandte Industrien für das Land Hessen e.V.
- IHK - Industrie- und Handelskammer zu Berlin
- IHK - Industrie- und Handelskammer Halle-Dessau
- IHK - Industrie- und Handelskammer für Koblenz
- IHK - Industrie- und Handelskammer für München und Oberbayern
- IHK - Industrie- und Handelskammer für Rheinhessen
- InnoNet HealthEconomy e.V
- Nationales Aktionsbündnis Impfen NABI e.V.
- Society for Immunotherapy of Cancer
- The Alliance for mRNA Medicines (AMM)
- Verband der Chemischen Industrie e.V. (VCI)
- Verband Forschender Arzneimittelhersteller e.V. (VFA)
- Zentrale zur Bekämpfung unlauteren Wettbewerbs e.V.
Interest Represented
Promotes their own interests or the collective interests of their members.
Financial Data
New Organisation: No
Closed Year (2025-01-01 to 2025-12-01)
Total Representation Costs: €100,000 - €199,999
Intermediaries:
| Name | Representation Costs |
|---|---|
| Acumen Public Affairs | €50,000 - €99,999 |
Grants Received:
| Source | Amount |
|---|---|
| European Investment Bank (Rwanda mRNA Manufacturing Hub) | €13,000,000 |
Current Year
Intermediaries: None Grants Received: None
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: BioNTech SE, Mainz, Germany.
